Aquavit Files NDAs for Neuromodulator for Hyperhidrosis, Shares Updates at AAD Annual Meeting


Botulinum Toxins have shown to be effective treatment options for hyperhidrosis, specifically axillary and palmar hyperhidrosis, and new options may be forthcoming. After submitting 2 investigational new drug (IND) applications this month for Aquatox™ for both primary axillary hyperhidrosis and for palmar hyperhidrosis, Aquavit Holdings shared details of its development program at the Annual Meeting of the American Academy of Dermatology in New Orleans, LA.

Also known as DTX-023, Aquatox is a highly purified injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Aquavit is initiating Phase 2 clinical trials soon for the treatment of primary axillary hyperhidrosis and palmar hyperhidrosis. Additionally, Aquavit says it is evaluating other potential therapeutic indications of botulinum toxins.

Aquavit is also developing Microtox™ (DTX-022), described as a first-of-its-kind, pan-facial microinjection of neurotoxins. DTX-022 features a novel route of administration with Aquavit’s microchannel delivery system. The company is actively seeking partners for its clinical trial program.